Executive Summary
HHS awarded $1.37B across 5 contracts in this period, with 70%+ concentrated in CMS IT/admin services signaling bullish stability for federal health IT providers through 2026-2029. Accenture's near-$800M FFE IT deal dominates, underscoring reliable revenue execution ($519M outlayed) amid high subaward flows. Neutrals in nonprofit UAC services and local gov utilities dilute public market impact, but ARPA-H's $162M potential in health research offers innovation upside.
Tracking the trend? Catch up on the prior All HHS Contracts digest from January 07, 2026.
Investment Signals(3)
- CMS IT/Admin Revenue Stability(HIGH)▲
Over $1B obligated to Accenture and First Coast for FFE IT and Medicare admin, with $713M already outlayed and options to $1.36B, indicating strong execution in NAICS 541512/524114 through 2026+.
- ARPA-H Health Research Expansion(MEDIUM)▲
$39M obligated (options to $162M) to Strategic Analysis for professional services, with $23M outlayed early, highlighting growth in advanced health R&D.
- Non-Profit/Gov Entity Dominance in Services(HIGH)▲
$241M to Acacia (UAC legal) and WSSC (NIH utilities) with no public equity exposure, limiting broader investor upside despite high outlays.
Risk Flags(2)
- Execution[HIGH RISK]▼
Cost-plus award fee and time/materials structures tie ~$1.1B to govt performance evaluations; subawards total $166M across deals may erode net retention.
- Regulatory[MEDIUM RISK]▼
Long periods to 2026-2029 expose $1.3B+ potential to CMS/NIH funding shifts or non-renewal post-current ends.
Opportunities(2)
- ◆
$354M+ in unobligated options across deals, plus extensions to 2027-2029, could double values for IT/research providers.
- ◆
ARPA-H focus signals rising HHS spend on health innovation services amid $162M potential.
Sector Themes(2)
- ◆
85% of value in CMS Medicare/FFE IT/admin contracts awarded via full/open competition, with 65%+ outlayed.
- ◆
30% to nonprofits/local gov for legal/utilities, bypassing public markets.
Watch List(3)
- 👁
{"entity"=>"Accenture Federal Services (ACN exposure)", "reason"=>"$791M deal is 58% of period total, with $193M options and 15% subawards", "trigger"=>"Q1 2026 outlay acceleration or 2027 extension"}
- 👁
{"entity"=>"Strategic Analysis ARPA-H contract", "reason"=>"$123M options upside in high-growth health R&D to 2029", "trigger"=>"Option exercise announcements"}
- 👁
{"entity"=>"CMS budget cycles", "reason"=>"Dominant $1B+ exposure across top contracts", "trigger"=>"FY2027 appropriations impacting renewals"}
Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 5 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC